Project Lead: Judit Erdös
Authors: Judit Erdös, NN
Duration: Q1 2026 to Q4 2026 (ongoing)
Language: English
The European HTA Regulation (HTAR) has been mandatory since January 2025. This means that the additional clinical benefit of all newly authorised oncology medicines and Advanced Therapy Medicinal Products (ATMPs) must be assessed in the form of Joint Clinical Assessments (JCAs). The AIHTA has been involved in the preparation of a JCA as a co-assessor since December 2025 and is expected to participate in a further one as an assessor/co-assessor in 2026.